{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:14:07Z","timestamp":1793121247310,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.aohep.2024.101772","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T12:11:16Z","timestamp":1734437476000},"page":"101772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The role of inflammasomes in hepatocellular carcinoma: Mechanisms and therapeutic insights"],"prefix":"10.1016","volume":"30","author":[{"given":"Valentina","family":"Arr\u00e8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Negro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Giannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.soc.2014.09.001","article-title":"Epidemiology of hepatocellular carcinoma","volume":"24","author":"Lafaro","year":"2015","journal-title":"Surg Oncol Clin N Am"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.12775\/JEHS.2023.49.01.002","article-title":"Advances and challenges in hepatocellular carcinoma: a comprehensive review","volume":"49","author":"Dorochowicz","year":"2023","journal-title":"J Educ, Health Sport"},{"issue":"3","key":"10.1016\/j.aohep.2024.101772_bib0003","doi-asserted-by":"crossref","first-page":"743","DOI":"10.7314\/APJCP.2012.13.3.743","article-title":"Risk factors of hepatocellular carcinoma - current status and perspectives","volume":"13","author":"Gao","year":"2012","journal-title":"Asian Pacific J Cancer Prevent"},{"key":"10.1016\/j.aohep.2024.101772_bib0004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/5584_2023_781","article-title":"Regulation of hepatocellular carcinoma epithelial-mesenchymal transition mechanism and targeted therapeutic approaches","volume":"1450","author":"Y\u00fcregir","year":"2024","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.aohep.2024.101772_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2953727","article-title":"Revisiting epithelial-to-mesenchymal transition in liver fibrosis: clues for a better understanding of the \"reactive\" biliary epithelial phenotype","volume":"2016","author":"Fabris","year":"2016","journal-title":"Stem Cells Int"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0030-1247131","article-title":"Molecular classification and novel targets in hepatocellular carcinoma: recent advancements","volume":"30","author":"Hoshida","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"7","key":"10.1016\/j.aohep.2024.101772_bib0007","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nrclinonc.2015.103","article-title":"Advances in targeted therapies for hepatocellular carcinoma in the genomic era","volume":"12","author":"Llovet","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.aohep.2024.101772_bib0008","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/path.2169","article-title":"Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations","volume":"212","author":"Audard","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.aohep.2024.101772_bib0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.21467","article-title":"Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets","volume":"45","author":"Boyault","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2024.101772_bib0010","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1053\/j.gastro.2011.02.006","article-title":"Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma","volume":"140","author":"Villanueva","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2024.101772_bib0011","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.aohep.2024.101772_bib0012","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.aohep.2024.101772_bib0013","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00535-020-01668-w","article-title":"Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: japanese subgroup analysis of the REACH-2 trial","volume":"55","author":"Kudo","year":"2020","journal-title":"J Gastroenterol"},{"issue":"15","key":"10.1016\/j.aohep.2024.101772_bib0014","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2024.101772_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jhep.2016.05.035","article-title":"Genetic profiling of hepatocellular carcinoma using next-generation sequencing","volume":"65","author":"Schulze","year":"2016","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0016","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhep.2015.08.028","article-title":"Hepatocellular carcinoma and lifestyles","volume":"64","author":"Saran","year":"2015","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.aohep.2024.101772_bib0017","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s12072-024-10692-4","article-title":"Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients","volume":"18","author":"Argenziano","year":"2024","journal-title":"Hepatol Int"},{"issue":"7","key":"10.1016\/j.aohep.2024.101772_bib0018","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.3390\/ijms23073778","article-title":"Tumor microenvironment of hepatocellular carcinoma: challenges and opportunities for new treatment option","volume":"23","author":"Sas","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.aohep.2024.101772_bib0019","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/hep.28835","article-title":"Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332\/\u03b13 integrin axis recovery of focal adhesion kinase ubiquitination","volume":"64","author":"Azzariti","year":"2016","journal-title":"Hepatology"},{"issue":"23","key":"10.1016\/j.aohep.2024.101772_bib0020","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.3390\/jcm12237469","article-title":"The complexity of the tumor microenvironment in hepatocellular carcinoma and emerging therapeutic developments","volume":"12","author":"Argentiero","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12943-019-1102-3","article-title":"Harnessing tumor-associated macrophages as aids for cancer immunotherapy","volume":"18","author":"Li","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.aohep.2024.101772_bib0022","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3389\/fimmu.2019.01643","article-title":"M1 macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1\u03b2 signaling","volume":"10","author":"Zong","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101772_bib0023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.aohep.2024.101772_bib0024","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41568-019-0123-y","article-title":"Diverging inflammasome signals in tumorigenesis and potential targeting","volume":"19","author":"Karki","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13238-013-0001-4","article-title":"Inflammasomes in cancer: a double-edged sword","volume":"5","author":"Kolb","year":"2014","journal-title":"Protein Cell"},{"key":"10.1016\/j.aohep.2024.101772_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110107","article-title":"Role of NLRP3 inflammasome in hepatocellular carcinoma: a double-edged sword","volume":"118","author":"Tang","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.aohep.2024.101772_bib0027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4291\/wjgp.v6.i3.43","article-title":"Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis","volume":"6","author":"Hammerich","year":"2015","journal-title":"World J Gastrointest Pathophysiol"},{"key":"10.1016\/j.aohep.2024.101772_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-0901-5_1","article-title":"Macrophage pattern recognition receptors in immunity, homeostasis and self tolerance","volume":"653","author":"Mukhopadhyay","year":"2009","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.aohep.2024.101772_bib0029","doi-asserted-by":"crossref","first-page":"1013.22","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.aohep.2024.101772_bib0030","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cell.2011.04.022","article-title":"NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis","volume":"145","author":"Elinav","year":"2011","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.aohep.2024.101772_bib0031","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.aohep.2024.101772_bib0032","doi-asserted-by":"crossref","first-page":"e2119","DOI":"10.1371\/journal.pone.0002119","article-title":"The nod-like receptor (NLR) family: a tale of similarities and differences","volume":"3","author":"Proell","year":"2008","journal-title":"PLoS ONE"},{"issue":"6510","key":"10.1016\/j.aohep.2024.101772_bib0033","doi-asserted-by":"crossref","first-page":"eaas8995","DOI":"10.1126\/science.aas8995","article-title":"HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation","volume":"369","author":"Magupalli","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.aohep.2024.101772_bib0034","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","article-title":"NLRP3 inflammasome in cancer and metabolic diseases","volume":"22","author":"Sharma","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.aohep.2024.101772_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978190","article-title":"NLRP3 inflammasome in digestive diseases: from mechanism to therapy","volume":"13","author":"Qiang","year":"2022","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.aohep.2024.101772_bib0036","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.aohep.2024.101772_bib0037","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/JLB.MR0318-096R","article-title":"Understanding early TLR signaling through the Myddosome","volume":"105","author":"Balka","year":"2019","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.aohep.2024.101772_bib0038","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coi.2020.01.005","article-title":"TRPM2, linking oxidative stress and Ca2+ permeation to NLRP3 inflammasome activation","volume":"62","author":"Wang","year":"2020","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"10.1016\/j.aohep.2024.101772_bib0039","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem Sci"},{"issue":"7371","key":"10.1016\/j.aohep.2024.101772_bib0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature10558","article-title":"Non-canonical inflammasome activation targets caspase-11","volume":"479","author":"Kayagaki","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.aohep.2024.101772_bib0041","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.immuni.2016.01.012","article-title":"Human monocytes engage an alternative inflammasome pathway","volume":"44","author":"Gaidt","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.aohep.2024.101772_bib0042","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fcell.2020.00139","article-title":"Involvement of nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 inflammasome in the pathogenesis of liver diseases","volume":"8","author":"Shi","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"10.1016\/j.aohep.2024.101772_bib0043","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/eji.201848070","article-title":"Role of AIM2 inflammasome in inflammatory diseases, cancer and infection","volume":"49","author":"Sharma","year":"2019","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.aohep.2024.101772_bib0044","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.4049\/jimmunol.2100449","article-title":"USP21 deubiquitinase regulates AIM2 inflammasome activation","volume":"207","author":"Hong","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.aohep.2024.101772_bib0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-023-01687-y","article-title":"The role of inflammasomes in human diseases and their potential as therapeutic targets","volume":"9","author":"Yao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0046","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3748\/wjg.v22.i1.253","article-title":"Current status and perspectives of immune-based therapies for hepatocellular carcinoma","volume":"22","author":"Aerts","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.aohep.2024.101772_bib0047","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.3390\/ijms24087640","article-title":"Predictive biomarkers for immune-checkpoint inhibitor treatment response in patients with hepatocellular carcinoma","volume":"24","author":"Ji","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.aohep.2024.101772_bib0048","article-title":"The role of NLRP3 inflammasome in hepatocellular carcinoma","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.aohep.2024.101772_bib0049","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21037\/jgo-22-471","article-title":"IL-1 receptor-associated kinase 1 participates in the modulation of the NLRP3 inflammasome by tumor-associated macrophages in hepatocellular carcinoma","volume":"13","author":"Chen","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.aohep.2024.101772_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110107","article-title":"Role of NLRP3 inflammasome in hepatocellular carcinoma: a double-edged sword","volume":"118","author":"Tang","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0051","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12964-023-01053-z","article-title":"Targeting and regulation of autophagy in hepatocellular carcinoma: revisiting the molecular interactions and mechanisms for new therapy approaches","volume":"21","author":"Hashemi","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"7","key":"10.1016\/j.aohep.2024.101772_bib0052","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3727\/096504018X15462920753012","article-title":"E2-Induced Activation of the NLRP3 inflammasome triggers pyroptosis and inhibits autophagy in HCC cells","volume":"27","author":"Wei","year":"2019","journal-title":"Oncol Res"},{"issue":"9","key":"10.1016\/j.aohep.2024.101772_bib0053","doi-asserted-by":"crossref","first-page":"e19542","DOI":"10.1016\/j.heliyon.2023.e19542","article-title":"Role of NLRP3 inflammasome activation in HCC cell progression","volume":"9","author":"Dai","year":"2023","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.aohep.2024.101772_bib0054","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s43440-020-00064-8","article-title":"Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis","volume":"72","author":"Zhang","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.aohep.2024.101772_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109570","article-title":"Antitumor effects of immunity-enhancing traditional Chinese medicine","volume":"121","author":"Wang","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.aohep.2024.101772_bib0056","article-title":"The effect and mechanism of chinese herbal formula sini tang in heart failure after myocardial infarction in rats","volume":"5629342","author":"Zhu","year":"2018","journal-title":"Evid Complement Alternat Med"},{"key":"10.1016\/j.aohep.2024.101772_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154249","article-title":"Shuanghua decoction exerts anticancer activity by activating NLRP3 inflammasome via ROS and inhibiting NF-\u03baB signaling in hepatocellular carcinoma cells","volume":"103","author":"Dai","year":"2022","journal-title":"Phytomed: Int J Phytother Phytopharmacol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0058","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3892\/ol.2020.11635","article-title":"Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a\/SIRT1 axis in liver cancer","volume":"20","author":"Chen","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.aohep.2024.101772_bib0059","article-title":"Inhibition of NEK7 suppressed hepatocellular carcinoma progression by mediating cancer cell pyroptosis","volume":"12","author":"Yan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.aohep.2024.101772_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115861","article-title":"NLRP3 inflammasome in hepatic diseases: a pharmacological target","volume":"217","author":"Ramos-Tovar","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101772_bib0061","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.30252","article-title":"NLR family pyrin domain-containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice","volume":"69","author":"Inzaugarat","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2024.101772_bib0062","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3389\/fimmu.2020.01444","article-title":"NLRP3 inflammasome activation in cancer: a double-edged sword","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Front Immunol"},{"issue":"88","key":"10.1016\/j.aohep.2024.101772_bib0063","first-page":"62","article-title":"Increased FNDC5\/Irisin expression in human hepatocellular carcinoma","volume":"88","author":"Gaggini","year":"2016","journal-title":"Peptides"},{"key":"10.1016\/j.aohep.2024.101772_bib0064","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bbrc.2021.10.041","article-title":"FNDC5 induces M2 macrophage polarization and promotes hepatocellular carcinoma cell growth by affecting the PPAR\u03b3\/NF-\u03baB\/NLRP3 pathway","volume":"582","author":"Liu","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.aohep.2024.101772_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.775462","article-title":"Targeting immune cells in the tumor microenvironment of HCC: new opportunities and challenges","volume":"9","author":"Hao","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"17","key":"10.1016\/j.aohep.2024.101772_bib0066","doi-asserted-by":"crossref","first-page":"9285","DOI":"10.3390\/ijms22179285","article-title":"NLRP3 deficiency in hepatocellular carcinoma enhances surveillance of NK-92 through a modulation of MICA\/B","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.aohep.2024.101772_bib0067","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/j.1349-7006.2008.00859.x","article-title":"Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma","volume":"99","author":"Kohga","year":"2008","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0068","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00430-008-0101-6","article-title":"Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells","volume":"198","author":"Tang","year":"2008","journal-title":"Med Microbiol Immunol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101772_bib0069","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jhep.2011.06.017","article-title":"Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence","volume":"56","author":"Kamimura","year":"2012","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.aohep.2024.101772_bib0070","doi-asserted-by":"crossref","first-page":"9285","DOI":"10.3390\/ijms22179285","article-title":"NLRP3 deficiency in hepatocellular carcinoma enhances surveillance of NK-92 through a modulation of MICA\/B","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.aohep.2024.101772_bib0071","first-page":"2429","article-title":"miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit proliferation of hep3B cells","volume":"15","author":"Wan","year":"2018","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.aohep.2024.101772_bib0072","doi-asserted-by":"crossref","first-page":"e89961","DOI":"10.1371\/journal.pone.0089961","article-title":"Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0073","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12903","article-title":"AIM2 in health and disease: inflammasome and beyond","volume":"297","author":"Kumari","year":"2020","journal-title":"Immunol Rev"},{"issue":"18","key":"10.1016\/j.aohep.2024.101772_bib0074","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.3390\/ijms21186535","article-title":"The emerging relevance of AIM2 in liver disease","volume":"21","author":"Lozano-Ruiz","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1016\/j.aohep.2024.101772_bib0075","doi-asserted-by":"crossref","first-page":"36185","DOI":"10.18632\/oncotarget.9154","article-title":"Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.aohep.2024.101772_bib0076","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","article-title":"Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin","volume":"22","author":"Hudson","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.aohep.2024.101772_bib0077","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1541-7786.MCR-05-0234","article-title":"Akt1 activation can augment hypoxia-inducible factor-1\u03b1 expression by increasing protein translation through a mammalian target of rapamycin\u2013independent pathway","volume":"4","author":"Pore","year":"2006","journal-title":"Mol Cancer Res"},{"issue":"2","key":"10.1016\/j.aohep.2024.101772_bib0078","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/OTT.S125039","article-title":"AIM2 regulates viability and apoptosis in human colorectal cancer cells via the PI3K\/Akt pathway","volume":"10","author":"Chen","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.aohep.2024.101772_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154454","article-title":"The role of AIM2 in human hepatocellular carcinoma and its clinical significance","volume":"245","author":"Zheng","year":"2023","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.aohep.2024.101772_bib0080","article-title":"Mechanisms and clinical trials of hepatocellular carcinoma immunotherapy","volume":"12","author":"Huang","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.aohep.2024.101772_bib0081","doi-asserted-by":"crossref","DOI":"10.1177\/1721727X231172025","article-title":"Inflammatory microenvironment and immunotherapy in hepatocellular carcinoma","volume":"21","author":"Liu","year":"2023","journal-title":"Eur J Inflamm"},{"issue":"3","key":"10.1016\/j.aohep.2024.101772_bib0082","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/cancers12030641","article-title":"Inflammatory mechanisms of HCC development","volume":"12","author":"Refolo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.aohep.2024.101772_bib0083","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/ijc.31827","article-title":"AIM2 deficiency reduces the development of hepatocellular carcinoma in mice","volume":"143","author":"Mart\u00ednez-Cardona","year":"2018","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0084","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cam4.4898","article-title":"A novel pyroptosis risk model composed of NLRP6 effectively predicts the prognosis of hepatocellular carcinoma patients","volume":"12","author":"Gao","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.aohep.2024.101772_bib0085","article-title":"Intestinal Candida albicans promotes hepatocarcinogenesis by up-regulating NLRP6","volume":"13","author":"Liu","year":"2022","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101772_bib0086","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/ijms21020496","article-title":"Crosstalk between NLRP12 and JNK during Hepatocellular Carcinoma","volume":"21","author":"Khan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.aohep.2024.101772_bib0087","doi-asserted-by":"crossref","first-page":"e40396","DOI":"10.7554\/eLife.40396","article-title":"NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte","volume":"8","author":"Udden","year":"2019","journal-title":"eLife"},{"issue":"22","key":"10.1016\/j.aohep.2024.101772_bib0088","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.3390\/cancers15225378","article-title":"Current trends in surgical management of hepatocellular carcinoma","volume":"15","author":"Angeli-Pahim","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.aohep.2024.101772_bib0089","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3904\/kjim.2014.29.2.149","article-title":"Newer treatments for advanced hepatocellular carcinoma","volume":"29","author":"Song","year":"2014","journal-title":"Korean J Intern Med"},{"issue":"8","key":"10.1016\/j.aohep.2024.101772_bib0090","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5306\/wjco.v11.i8.589","article-title":"Novel molecular targets in hepatocellular carcinoma","volume":"11","author":"Chow","year":"2020","journal-title":"World J Clin Oncol"},{"issue":"04","key":"10.1016\/j.aohep.2024.101772_bib0091","first-page":"281","article-title":"Application and significance of molecular targeted nanotechnology in diagnosis and treatment of hepatocellular carcinoma","volume":"23","author":"Qin","year":"2017","journal-title":"Chin J Hepatobil Surg"},{"issue":"4","key":"10.1016\/j.aohep.2024.101772_bib0092","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/imm.13677","article-title":"Application of adoptive cell therapy in hepatocellular carcinoma","volume":"170","author":"Li","year":"2023","journal-title":"Immunology"},{"issue":"18","key":"10.1016\/j.aohep.2024.101772_bib0093","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.3390\/molecules29184405","article-title":"Targeted drug delivery strategies for the treatment of hepatocellular carcinoma","volume":"29","author":"Liu","year":"2024","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0094","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3748\/wjg.v22.i1.253","article-title":"Current status and perspectives of immune-based therapies for hepatocellular carcinoma","volume":"22","author":"Aerts","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.aohep.2024.101772_bib0095","first-page":"581","article-title":"Cancer nanotechnology: enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy","volume":"14","author":"Sun","year":"2019","journal-title":"Asian J Pharm Sci"},{"issue":"1","key":"10.1016\/j.aohep.2024.101772_bib0096","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1038\/s41467-020-19554-7","article-title":"Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting","volume":"11","author":"Brocker","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.aohep.2024.101772_bib0097","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00280-020-04033-z","article-title":"Novel complementary antitumour effects of celastrol and metformin by targeting I\u03baB\u03baB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis","volume":"85","author":"Saber","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.aohep.2024.101772_bib0098","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3390\/cancers16081491","article-title":"Induction of the inflammasome pathway by tyrosine kinase inhibitors provides an actionable therapeutic target for hepatocellular carcinoma","volume":"16","author":"Tutusaus","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.aohep.2024.101772_bib0099","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ptr.6332","article-title":"an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells","volume":"33","author":"Shi","year":"2019","journal-title":"Phytother Res"},{"issue":"6","key":"10.1016\/j.aohep.2024.101772_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101532","article-title":"A novel role of AIM2 inflammasome-mediated pyroptosis in radiofrequency ablation of hepatocellular carcinoma","volume":"29","author":"He","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2024.101772_bib0101","article-title":"Inflammasome components as new therapeutic targets in inflammatory disease","author":"Coll","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.aohep.2024.101772_bib0102","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.3390\/cancers12092652","article-title":"Cancer-associated fibroblasts: versatile players in the tumor microenvironment","volume":"12","author":"Ganguly","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268124005556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268124005556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:39:49Z","timestamp":1777783189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268124005556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1665268124005556"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2024.101772","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of inflammasomes in hepatocellular carcinoma: Mechanisms and therapeutic insights","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2024.101772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101772"}}